‘Fulminant’ type 1 diabetes seen in patients on checkpoint inhibitors

A small minority of cancer patients treated with immune checkpoint inhibitors have developed a fulminant form of type 1 diabetes, report Australian clinicians.

In a case series of nine patients, they warn that the real world incidences of immunotherapy-induced type 1 diabetes could be significantly higher than the 0.4% reported in checkpoint trials.

More patients are likely to be affected in the future as checkpoint inhibitors become standard care for more tumour types, add the researchers led by endocrinologist Professor Peter Colman of the Royal Melbourne Hospital and